Prot #KAR-012: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia

Project: Research project

Project Details

StatusActive
Effective start/end date3/19/24 → 3/19/27

Funding

  • Quintiles, Inc. (Prot #KAR-012 // Prot #KAR-012)
  • Karuna Therapeutics, Inc. (Prot #KAR-012 // Prot #KAR-012)